US 12,290,553 B2
Method for vaccination against a self-antigen in a human patient
Gergana Galabova, Vienna (AT); Sabine Schmidhuber, Vienna (AT); Achim Schneeberger, Vienna (AT); Arne Von Bonin, Vienna (AT); Dorian Winter, Vienna (AT); and Jana Zimmermann, Vienna (AT)
Assigned to AC Immune SA, Lausanne (CH)
Appl. No. 15/772,572
Filed by AC Immune SA, Lausanne (CH)
PCT Filed Nov. 2, 2016, PCT No. PCT/EP2016/076372
§ 371(c)(1), (2) Date May 1, 2018,
PCT Pub. No. WO2017/076873, PCT Pub. Date May 11, 2017.
Claims priority of application No. 15192794 (EP), filed on Nov. 3, 2015.
Prior Publication US 2019/0091306 A1, Mar. 28, 2019
Int. Cl. A61P 25/16 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01)
CPC A61K 39/0008 (2013.01) [A61K 39/0005 (2013.01); A61K 39/0007 (2013.01); A61P 25/16 (2018.01); A61P 37/06 (2018.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/577 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6081 (2013.01); A61K 2039/627 (2013.01)] 10 Claims
 
1. A method for vaccination against a self-antigen in a human patient wherein a dose with an effective amount of a self-antigen is administered to the patient to elicit a primary immune response, wherein the patient is subjected to a boost administration of said self-antigen, wherein the amount of the self-antigen in the dose for the boost administration is at least 50 μg and is at least 200% higher than the amount of the self-antigen in the dose used in the administration for the primary immune response, wherein the self-antigen is selected from the group consisting of proprotein convertase subtilisin/kexin type 9 (PCSK9), and an alpha synuclein antigen, and wherein the boost administration is administered at least 6 months after the first administration of the self-antigen for eliciting the primary immune response.